(Q35184329)

7 August 2017

1 reference

title

Chronic myelogenous leukemia: a review and update of therapeutic strategies (English)

1 reference

7 August 2017

1 reference

6

Hagop M Kantarjian

1 reference

7 August 2017

2

Stefan Faderl

1 reference

7 August 2017

4

Jorge Cortes

1 reference

7 August 2017

3

Susan O'Brien

1 reference

7 August 2017

Guillermo Garcia-Manero

series ordinal

1

object named as

Guillermo Garcia-Manero

1 reference

7 August 2017

5

Moshe Talpaz

1 reference

7 August 2017

language of work or name

English

0 references

publication date

1 August 2003

1 reference

7 August 2017

1 reference

7 August 2017

98

1 reference

7 August 2017

3

1 reference

7 August 2017

437-457

1 reference

Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion.

7 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

Chronic myelocytic leukemia: Clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

The biology of chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Acute leukaemia in bcr/abl transgenic mice

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Clinical course and therapy of chronic myelogenous leukemia with interferon-alpha and chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Population-based age- and sex-specific incidence rates in the 4 main types of leukaemia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

The molecular genetics of Philadelphia chromosome-positive leukemias

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Significance and correlations of molecular analysis results in patients with Philadelphia chromosome-negative chronic myelogenous leukemia and chronic myelomonocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

BCR rearrangement-negative chronic myelogenous leukemia revisited

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Philadelphia chromosome-negative chronic myelogenous leukemia with rearrangement of the breakpoint cluster region. Long-term follow-up results

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Clinical and prognostic features of Philadelphia chromosome-negative chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Progressive de novo DNA methylation at the bcr-abl locus in the course of chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Chronic myelogenous leukaemia with p185(BCR/ABL) expression: characteristics and clinical significance

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Expression of p210 and p190 BCR-ABL due to alternative splicing in chronic myelogenous leukaemia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Neutrophilic-chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Interaction of the receptor tyrosine kinase p145c-kit with the p210bcr/abl kinase in myeloid cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

The CRKL adaptor protein transforms fibroblasts and functions in transformation by the BCR-ABL oncogene

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

BCR/ABL-mediated leukemogenesis requires the activity of the small GTP-binding protein Rac.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Signalling pathways: jack of all cascades

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Ras recruits Raf-1 to the plasma membrane for activation by tyrosine phosphorylation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

The cytogenetic scenario of chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

p53 loss and point mutations are associated with suppression of apoptosis and progression of CML into myeloid blastic crisis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Molecular defects associated with the acute phase CML.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16-year period

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Characteristics of accelerated disease in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Bone marrow transplantation for chronic myeloid leukaemia: the effects of differing criteria for defining chronic phase on probabilities of survival and relapse

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte-macrophage colony-stimulating factor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Blast crisis of chronic granulocytic leukemia. Morphologic variants and therapeutic implications

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

A study of prognostic factors in blast crisis of Philadelphia chromosome-positive chronic myelogenous leukaemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Terminal-phase chronic myelogenous leukemia: approaches to treatment.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

'Lymphoid' blast crisis of chronic myeloid leukaemia is associated with distinct clinicohaematological features.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Clinical and prognostic features of patients with Philadelphia chromosome-positive chronic myelogenous leukemia and extramedullary disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

The relevance of reticulin stain-measured fibrosis at diagnosis in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Significance of cytogenetic clonal evolution in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Proposal for a simple synthesis prognostic staging system in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Results of therapy with interferon alpha and cyclic combination chemotherapy in patients with philadelphia chromosome positive chronic myelogenous leukemia in early chronic phase

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Suppression of cytogenetic clonal evolution with interferon alfa therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Expression of interferon regulatory factor 4 in chronic myeloid leukemia: correlation with response to interferon alfa therapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Induction of interferon regulatory factors 2'-5' oligoadenylate synthetase, P68 kinase and RNase L in chronic myelogenous leukaemia cells and its relationship to clinical responsiveness

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Fluorescence in situ hybridization for the detection and monitoring of the Ph-positive clone in chronic myelogenous leukemia: comparison with metaphase banding analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Fluorescence in situ hybridization (FISH) on peripheral blood smears for monitoring Philadelphia chromosome-positive chronic myeloid leukemia (CML) during interferon treatment: a new strategy for remission assessment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Detection of minimal residual disease by polymerase chain reaction of bcr/abl transcripts in chronic myelogenous leukaemia following allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Quantitative determination of the hybrid Bcr-Abl RNA in patients with chronic myelogenous leukaemia under interferon therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Quantitative measurement of BCR/abl transcripts using real-time polymerase chain reaction

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Quantitative monitoring of BCR/ABL transcript during STI-571 therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Clonal Ph-negative hematopoiesis in CML after therapy with imatinib mesylate is frequently characterized by trisomy 8.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Emergence of new clonal abnormalities following interferon-alpha induced complete cytogenetic response in patients with chronic myeloid leukemia: report of three cases.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Therapeutic choices in younger patients with chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Initial therapy for chronic myelogenous leukemia: playing the odds.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Chronic myeloid leukemia: current treatment options

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Myleran in chronic myeloid leukaemia; results of treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Hydroxyurea therapy in chronic myelogenous leukemia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

The effect of pretransplant interferon therapy on the outcome of unrelated donor hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in first chronic phase.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Interferon alpha for chronic myeloid leukemia relapsing after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Combined interferon alfa-2a and cytosine arabinoside as first-line treatment for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Imatinib alone and in combination for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Phase 1 study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Treatment of patients with advanced chronic myelogenous leukemia with interferon-alpha-2b and continuous oral cytarabine ocfosfate (YNK01): a pilot study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Homoharringtonine: history, current research, and future direction

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

The basis of T-cell-mediated immunity to chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

GM-CSF can improve the cytogenetic response obtained with interferon-alpha therapy in patients with chronic myelogenous leukemia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11520

7 January 2021

Identifiers

DOI

10.1002/CNCR.11520

1 reference

release_saofrwpqsbaf7lxtkceoxqqqny

7 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/saofrwpqsbaf7lxtkceoxqqqny

24 November 2022

mapped directly with Wikidata item

1 reference